As we transition the business during 2009, we anticipate that sales of the Bravo system will add approximately $12 million to our top-line results. Larry Colton, Bruce Crabtree, Eric Mandus, Jonathan Minnen, David Santi, Michelle Edwards, Jeff Bekiares, Emily Cacioppo, Julie Sebastian, and Chris Yarbrough were also part of the SGR team.ATLANTA (December 18, 2008) — On December 8th, a group of Smith, Gambrell & Russell attorneys assisted client Given Imaging Ltd. in finalizing the acquisition of the Bravo(R) pH monitoring business for the diagnosis of Gastroesophageal Reflux Disease (GERD) from Medtronic (NYSE: MDT) for $20 million.“We were delighted to be transaction counsel for one of Israel’s premier companies,” said Jonathan Minnen, relationship partner at SGR for Given Imaging, and chair of the Firm’s Israel Practice Group. Occasional heartburn is normal, but chronic heartburn caused by GERD can affect daily activities and damage the esophagus. During this 12-month period, Given Imaging intends to complete the transition of the Bravo system manufacturing operations to Israel.© 2020 Smith, Gambrell & Russell, LLPThe only wireless, catheter-free pH test for GERD, the Bravo system uses a disposable capsule temporarily placed in the esophagus that measures pH levels and transmits the data to an external receiver. Datamonitor estimates that around 147 million people in the US, Japan, France, Germany, Italy, Spain and the UK (around 20% of the population) suffer from GERD.A small portion of the purchase price is contingent upon Medtronic completing the development of a new capsule delivery system already underwayDuring the first 12 months after the transaction closes, Medtronic will continue to supply the Bravo products to Given Imaging. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of significant litigation, (8) our ability to obtain reimbursement for our product from government and commercial payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, and (11) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2007.